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Background: Metastatic melanoma is a lethal skin cancer and its incidence is rising every year. It represents a
challenge for oncologist, as the current treatment options are non-curative in the majority of cases; therefore, the
effort to find and/or develop novel compounds is mandatory. Pemetrexed (Alimta®, MTA) is a multitarget antifolate
that inhibits folate-dependent enzymes: thymidylate synthase, dihydrofolate reductase and glycinamide
ribonucleotide formyltransferase, required for de novo synthesis of nucleotides for DNA replication. It is currently
used in the treatment of mesothelioma and non-small cell lung cancer (NSCLC), and has shown clinical activity in
other tumors such as breast, colorectal, bladder, cervical, gastric and pancreatic cancer. However, its effect in human
melanoma has not been studied yet.
Results: In the current work we studied the effect of MTA on four human melanoma cell lines A375, Hs294T, HT144
and MeWo and in two NSCLC cell lines H1299 and Calu-3. We have found that MTA induces DNA damage, S-phase
cell cycle arrest, and caspase- dependent and –independent apoptosis. We show that an increment of the intracellular
reactive oxygen species (ROS) and p53 is required for MTA-induced cytotoxicity by utilizing N-Acetyl-L-Cysteine (NAC)
to blockage of ROS and p53-defective H1299 NSCLC cell line. Pretreatment of melanoma cells with NAC significantly
decreased the DNA damage, p53 up-regulation and cytotoxic effect of MTA. MTA was able to induce p53 expression
leading to up-regulation of p53-dependent genes Mcl-1 and PIDD, followed by a postranscriptional regulation of Mcl-1
improving apoptosis.
Conclusions: We found that MTA induced DNA damage and mitochondrial-mediated apoptosis in human melanoma
cells in vitro and that the associated apoptosis was both caspase-dependent and –independent and p53-mediated. Our
data suggest that MTA may be of therapeutic relevance for the future treatment of human malignant melanoma.
Keywords: Pemetrexed, MTA, Antifolates, DNA damage, Apoptosis, MelanomaBackground
Melanoma is one of the less common types of skin
cancers, but nevertheless causes the majority of skin
cancer-related deaths. In 2010, more than 60,000 new
cases of invasive melanoma were diagnosed in the
United States, with more than 7,000 recorded related
deaths; according to the 2011 WHO report, about
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reproduction in any medium, provided the oryear [1,2]. The standard treatment for localized mel-
anoma is surgical excision, but melanoma that has
spread to distant sites is rarely curable with standard
therapy. The most active chemotherapy for metastatic
melanoma is Dacarbazine (DTIC). However, this drug
causes cell shrinkage in only 8-20% of treated
patients, the response is partial and it lasts for a mere
4 to 6 months. Immunotherapy with interleukin-2 (IL-
2) or interferon (IFN) at high-doses has been found
to increase relapse-free survival (RFS) and overall sur-
vival (OS), but the high-dose regimes have important
side effects. Therefore the identification of new agentsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Pemetrexed (MTA) is a novel multitarget antifolate
with promising clinical activity. At present, it is a first
line therapy against mesothelioma and non small cell
lung cancer (NSCLC). However, its role in other malig-
nancies and particularly in malignant melanoma has not
yet been studied. MTA targets the folate-dependent
enzymes thymidylate synthetase (TS), dihydrofolate
reductase (DHFR) and glycinamide ribonucleotide for-
myltransferase (GARFT), all of which are involved in the
de novo biosynthesis of purines and pyrimidines, thereby
inducing an imbalance in the nucleotide pool and conse-
quent DNA damage [3]; nevertheless, the precise details
of its mechanism of action remain unknown.
One of the many effector mechanisms involved in
the control and regulation of apoptosis is the cellular
redox status which is determined by the balance
between the rates of production and breakdown of re-
active oxygen and/or nitrogen species (ROS; RNS).
The mitochondrion is the major intracellular source
of ROS and [4] low levels of ROS are maintained in
healthy cells due to the activity of various antioxidant
systems. However, the tumor cell response to death
stimuli has been shown to be a function of the cellu-
lar redox status and compounds which induce a sig-
nificant increase in intracellular H2O2 are known to
facilitate death execution by promoting DNA damage
and/or genomic instability [5,6]. Following intracellu-
lar stress stimuli in response to DNA damage, p53
becomes activated and induces expression of several
genes promoting cell cycle arrest and apoptosis [7].
In the present study we have evaluated the cytotoxic
effects of MTA on different human melanoma cell
lines. We found that MTA induces caspase-dependent
and -independent apoptosis in human melanoma cells
through intracellular ROS accumulation, which in turn
promotes DNA damage and consequent p53-regulated
gene expression changes. These findings indicate that
MTA may have important novel therapeutic characteristics
for the treatment of human metastatic melanoma.
Methods
Chemicals and reagents
Dulbecco’s Modified Eagle’s Medium (DMEM), Eagle’s
Minimum Essential Medium (EMEM), RPMI 1640, so-
dium pyruvate, sodium bicarbonate, L-glutamine, strepto-
mycin/penicillin antibiotic solution and fetal bovine serum
(FBS) were all obtained from Cambrex (Cambrex Bio
Science, Verviers, Belgium). Culture flasks, 96-, 24- and
6-well plates and centrifuge tubes were from Corning
Incorporated (NY, USA). The XTT viability assay kit was
purchased from Roche Molecular Biochemicals, and MTA
was purchased from Lilly (Lilly France S.A.S, Fegersheim,France). Propidium iodide (PI), dimethylsulfoxide
(DMSO), Triton X-100, bovine serum albumen (BSA),
N-Acetyl-L-Cysteine (NAC), polyclonal rabbit anti
cleaved-caspase-3 antibody and anti-actin antibody were
purchased from Sigma Chemical Co. (St. Louis, MO,
USA). Fluorescent labelled goat anti-rabbit IgG sec-
ondary antibody (Alexa Fluor®) and oxidation-sensitive
fluorescent 2′,7′-dichlorodihydro-fluoresceindiacetate
reagent (DCFH-DA) were from Molecular Probes
(Europe BV, Leiden, The Netherlands). Mouse anti-cyt
c monoclonal antibody, caspase colorimetric protease
assay kit, caspase-2 (Z-VDVAD-FMK), -3 (Z-DEVD-
FMK), -8 (Z-IETD-FMK), -9 (Z-LEHD-FMK), -10 (Z-
AEVD-FMK) inhibitors and general caspase inhibitors
(Z-VAD-FMK) were purchased from Biovision
(Biovision Research Products, Mountain View, USA). Don-
key anti-goat secondary antibody was from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA). HRP-labeled
goat anti-rabbit IgGs and goat anti-mouse IgGs were pur-
chased from Pierce Biotechnology Inc. (Meridian Rd.,
Rockford, USA). Acrylamide and bis-acrylamide solutions
and Precision Plus Protein Standards were obtained from
Bio-Rad Laboratories (Hercules, CA, USA).
Cells and culture conditions
A375, Hs294T, HT144, MeWo, Calu-3 and H1299 cell
lines were obtained from the American Type Culture
Collection, ATCC (Rockville, Maryland). Primary
mouse embryo fibroblasts (PMEF) were obtained from
Millipore Corporation, MA, USA. Human melanoma
cell lines A375, HT144 and Hs294T were maintained
in cell culture medium supplemented with 10% FBS
as described by ATCC. MeWo melanoma cell line
and Calu-3 lung adenocarcinoma cell lines were
maintained in minimum essential medium (Eagle)
with 2 mM L-glutamine and Earle’s BSS adjusted to
contain 1.5 g/L sodium bicarbonate, 0.1 mM non-es-
sential amino acids and 1.0 mM sodium pyruvate and
10% FBS as described by ATCC. The H1299 lung car-
cinoma cell line was maintained in RPMI 1640
medium with 2 mM L-glutamine adjusted to contain
1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM
HEPES, and 1.0 mM sodium pyruvate and 10% FBS
as described by ATCC.
Employed melanoma cell lines have different p53
genetic status as shown in Table 1.
MTA was dissolved in phosphate buffered saline
(PBS) at 2 mg/ml and stored at −80°C until required.
Cells were incubated for various periods of time with
different concentrations of MTA (0.17-10 μM).
To verify the effect of ROS on MTA-induced cell
death, ROS production was blocked by adding
10 mM N-acetyl-cysteine (NAC) 1 h before exposure to
MTA.
Table 1 p53 genotype of employed cell lines
A375 Hs294T HT144 MeWo Calu-3 H1299
TP53 wt wt wt c.772G>A c.711G>T 100% del.
c.949C>T
According to COSMIC database from Sanger institute (http://www.sanger.ac.uk/
genetics/CGP/cosmic) and “The TP53 web site” (http://p53.free.fr/Database/
Cancer_cell_lines/p53_cell_lines.html) the p53 status varies among the
employed cell lines. A375, Hs294T and HT144 melanoma cell lines show a wt
p53 while MeWo and Calu-3 have puntual mutations that seem to do not
compromise its functional activity. On the other hand, H1299 does not show
any p53 activity due to its 100% homozygous deletion.
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Human cells were seeded into flat-bottomed 96-well
microtiter plates at a density of 104 cells per well in
100 μl of culture medium and allowed to attach to the
wells overnight. Cells were treated with different concen-
trations of MTA (0–10 μM) for 24–72 h. Controls with-
out MTA exposure were included in each experiment.
Cell proliferation was determined by the colorimetric
XTT viability assay [8]. The concentration of MTA
required to inhibit viability by 50% (IC50) was deter-
mined using GraphPad Prism software (La Jolla, CA
92037, USA). All experiments were performed in tripli-
cate, and the presented data represent the mean of three
independent experiments.
Clonogenic assay (colony-forming assay)
To determine the effect of MTA on cellular colony for-
mation, 104 cells per well were seeded in 6 well plates
and allowed to adhere overnight. The cells were treated
with 0.84 μM MTA for 24 h. The culture medium was
subsequently replaced with MTA-free culture medium
and the cells were incubated for 10 more days. The col-
onies were fixed with ice-cold methanol, stained with
crystal violet, and viewed under a Nikon microscope
(Nikon Eclipse TE2000-E); images were processed using
NIS-Elements AR 2.31 software. All experiments were
performed in triplicate, and the presented data represent
the mean of three independent experiments.
Morphological assays of apoptosis
Nuclear staining and fluorescent microscopy
Morphological evaluation of the nucleus before and after
MTA exposure was performed by nuclear staining with
PI as described previously [8]. Cells were viewed and
analysed using a confocal microscope (Olympus FV 500),
and images were obtained by sequential acquisition to
avoid overlap.
Electron microscopy
For transmission electron microscopy (TEM), adherent
cells were washed twice with 0.1 M cacodylate buffer,
detached using a cell scraper, and mixed with cells float-
ing in media. Cells were then centrifuged at 625 g for7 min, and pellets were prefixed in 2.5% glutaraldehyde in
0.1 M cacodylate buffer for 1 h, followed by post fixation in
1% osmium tetraoxide (OsO4) in 0.2 M cacodylate buffer.
Cells were subsequently dehydrated in an ascending graded
ethanol series, embedded in resin, and polymerized for 48 h
at 60 º C. Ultrathin sections were stained with uranyl acetate
and examined using a Philips EM 208 electron microscope
(Philips Electronic Instruments, Eindhoven, Netherlands).
Cell cycle analysis
To quantify hypodiploid cells and analyze the cell cycle
distribution of MTA-treated and untreated melanoma
cells, these were subjected to flow cytometry analysis as
described previously [8]. Analysis was performed on at
least 10,000 cells using a Cytomics FC500 MPL (Beck-
man Coulter).
In transient knockdown of p53 transcriptional activity,
cell cultures were pretreated with 30 μM of pifithrin-
alpha (PFT-alpha) during 4 h. Subsequently, cell cultures
were exposed to 0.17 and 0.82 μM MTA during 24 and
48 h. Finally, cells were stained and subjected to flow
Cytometry.
Mitochondrial membrane potential assay
The mitochondrial membrane potential (ΔΨm) of
MTA-treated and untreated cells was analysed using
DIOC6 as previously described [9]. For all conditions,
10,000 cells were analysed using a Cytomics FC 500MPL
(Beckman Coulter).
Quantification of reactive oxygen species (ROS)
To measure ROS production of cells before and after
MTA exposure, 20 μM DCFH-DA was used as described
previously [10]. For all conditions, 10,000 cells were ana-
lysed using a Cytomics FC 500MPL (Beckman Coulter).
Comet assay
The comet assay (also known as single cell electrophor-
esis) was performed as described previously [8]. Digital
images were obtained using a Nikon Eclipse TE2000-E
fluorescence microscope.
SDS-PAGE and immunoblotting
MTA-treated and untreated human melanoma cells were
harvested by trypsinization. Cytosol and mitochondrial
extracts were obtained by digitonin fractionation as pre-
viously described [11]; total cell lysate was prepared by
resuspending pelleted cells in ice cold lysis buffer (1%
Igepal, 1% Triton X-100, 20 mM Tris pH 7.3, 140 mM
NaCl, 1 mM EDTA and water) containing protease and
phosphatase inhibitors (3% protease inhibitor cocktail,
10 mM NaF, 10 mM NaPPi, 1 mM Sodium Vanadate,
1 mM PMSF) followed by 30 min incubation on ice.
Aliquots of lysate were dissolved in Laemmli sample
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membrane with the iBlot® Gel Transfer Device as described
by the manufacturer. The following antibodies were used
for immunoblotting: anti-cyt c (0.2 μg/ml), anti-actin
(1:200) from Sigma, anti-Mcl1 (25 μg/ml) from R&D, anti-
AIF (1:200) and anti-p53 (1:100) from SCBT, anti-PUMA
(1:500) from ThermoScientific primary antibodies, and
horseradish peroxidase (HRP)-conjugated secondary anti-
bodies (1:5,000) both from ThermoScientific.
Images were acquired with the image analyzer G:Box
(Syngene) and densitometry was carried out with the
software GeneTools (Syngene).
Immunocytochemistry
Cells were fixed in ice cold 70% ethanol for 30 min at 4°
C before blocking with 1% BSA (v/v) for 1 h at room
temperature. Primary antibodies diluted in 1% BSA buf-
fer were added for overnight incubation at 4°C: anti-
cleaved caspase-3 (1:500) and anti-cyt c antibody (2 μg/
ml). After cells were washed, they were incubated for 1 h
at room temperature in the corresponding labeled
secondary antibodies. Nuclei were stained with Hoechst
(1 μg/ml). Cells were viewed and analysed with a con-
focal microscope (Olympus FV 500) and the images were
obtained by sequential acquisition to avoid overlap.
Caspase activity assay
Caspase-2, -3, -8, -9 and −10 activities were measured in
cell extracts (200 μg), using a colorimetric assay kit fol-
lowing the manufacturer’s instructions. Assays were per-
formed in triplicate on 96-well plates using a microtiter
plate reader at 405 nm. Fold increase in caspase activity
was measured as caspase activity of MTA-treated cells
divided by the corresponding activity in control cells.
Caspase inhibitors were used to confirm the dependency
of apoptosis on caspase activation. In brief, cells were pre-
treated with 25 μM caspases-2, -3, -8, -9, -10 and general
caspase inhibitors for one hour, followed by treatment with
MTA. Proliferation was subsequently evaluated with an
XTT proliferation kit as described above.
Real time RT-PCR
The level of expression of genes of interest was mea-
sured in each sample by one step real-time PCR using
human validated TaqMan Gene Expression Assays (Ref.
Hs01034253_m1 (P53), Hs00248075_m1 (BBC3),
Hs00388035_m1 (LRDD) and Hs00172036_m1 (Mcl-1)
from Applied Biosystems) with the Human RPLP0
(large ribosomal protein) Taqman Assay as the en-
dogenous control. Three replicates were run for each
sample in 96-well plates and 200 ng RNA were used
for each reaction.
Assays were carried out in a 7900 HT Real Time PCR
System (Applied Biosystems, Foster City, CA, USA) andanalyses were done by the ΔΔCt method using the RQ
manager software.
Gene silencing assays
Melanoma cells were seeded in 12-well plates with
corresponding medium without antibiotics overnight.
The medium was replaced with fresh medium without
serum and antibiotics. Silencing was performed using
Lipofectamine and OptiMEM® following the instruc-
tions provided by the manufacturer. Briefly, 60 nM of
commercially available p53 siRNA (Ambion) or nega-
tive control was mixed with 50 μl OptiMEM® and
also, lipofectamine was mixed with 50 μl OptiMEM®.
Both combinations were mixed and incubated for 20
min at 37°C. Finally the cells in each well were then
transfected with this mixture. After 6 h, serum was
added to a final concentration of 10%. 24 h later, cell
culture medium was replaced with MTA-containing
medium.
RNA and proteins were extracted using NucleoSpin
miRNA Nucleic Acid and Protein Pufification (ref:
740971 from Macherey-Nagel)
Statistical analysis
The statistical significance of differences between sample
means was determined using the Student t-test; p values
of< 0.05 were considered to be statistically significant.
Results
MTA induced apoptosis in human melanoma cells
We assessed the effect of MTA on cell proliferation
using the XTT method on four human melanoma cell
lines, on two types of NSCLC which constitute a positive
control and on MEF cells to evaluate MTA cytotoxicity
on non-tumoral cells. Cell viability decreased in a dose-
and time-dependent manner in response to MTA, in all
the studied human melanoma cell lines and in the posi-
tive control cell line Calu-3, but not in MEF or H1299,
which lacks p53 expression due to a homozygous partial
deletion (Figure 1 A and B).
Results of the clonogenic assay were consistent with the
XTT data; MTA showed a negative effect on the colony for-
mation ability of the A375, HT144, MeWo and Hs294T
melanoma cell lines, but not on H1299 (Figure 1C and D).
Morphological changes in the MTA-treated human
melanoma cells were studied by fluorescent microscopy
of cells stained with PI and by transmission electron
microscopy, to evaluated ultrastructural characteristics.
These studies revealed changes typical of apoptosis, such
as nuclear condensation, fragmentation and margination
and the dispersal of the nuclear fragments into the cyto-
plasm (Figure 2A).
Subsequently, we quantified apoptosis by flow cyto-
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Figure 1 Effects of MTA on human melanoma cell viability (A) A375, Hs294T, HT144 and MeWo human melanoma cells were treated with
different doses of MTA for 24, 48 and 72 h and cell viability was assessed by mean of the XTT viability assay. MTA significantly reduced cell
viability in all melanoma cell lines and in Calu-3 while there was no significant effect on H1299 (a human NSCLC lacking p53 expression).
Presented values are mean of at least 2 independent experiments. The IC50 values for MTA in A375, Hs294T, HT144 and MeWo human melanoma
cells were 0.27, 0.41, 0.32 and 0.99 μM, respectively and 10 μM for the Calu-3 NSCLC line. Data represent mean ± SD of six determinations in three
separate experiments for each cell line. (B) Effect of MTA on mouse embryonic fibroblast (MEF). Cells were exposed to the indicated MTA doses
for 24, 48 and 72 h (only results of 72 h are shown). There was no significant cytotoxic effect on MEF cell line. Data represent mean ± SD of six
determinations in two separate experiments. (C) Effect of MTA on the colony-forming ability of human melanoma cells and NSCLC cells. Cells
were exposed to 0.84 μM MTA for 24 h followed by incubation in MTA-free culture medium for 10 days before performance of crystal violet
staining and counting of colonies. MTA significantly reduced colony-forming ability in human melanoma cells and in Calu-3 cells, but not in the
H1299 cell line, corroborating results obtained in the viability assay. *p< 0.05 (Student t-test). (D) Colony-forming ability: details of A375 cell line
formed colonies growing in MTA-free medium (control) and in MTA-containing medium. This micrographs show that not only the amount of
colonies buy also the morphology of formed colonies changed which are composed for significantly less number of cells.
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Figure 2 MTA induced apoptosis in human melanoma cell lines (A) The nature of cell death was identified by studying morphological changes
which were apparent via immunocytochemistry and electron microscopy. Top: A375 representative fluorescence microscopy of nuclei stained with PI
before and after MTA exposure. All fields were photographed at a magnification of 40 X. Bottom: A375 representative TEM images of cells before and after
MTA exposure. Both techniques reveal that MTA exposure induced morphological changes such as DNA fragmentation and marginalization (arrows),
which are characteristic of apoptosis. (B, C) Quantification of the extent of apoptosis was carried out by cell cycle analysis. Cells lines were treated with two
different concentrations of MTA for 24, 48 and 72 h and analysed by flow cytometry. The results illustrated in (B) for Hs294T line are representative and the
results for all cell lines are summarized in the table (C). Results are expressed as a percentage of the cell population in the subGo-G1 and S phases of three
independent measurements. Cultures treated with MTA showed a time- and dose-dependent increase in their percentage of hypodiploid cells, with a
modification of cell percentages in the S-phase of the cell cycle.
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hypodiploid cells in subG0/G1 after 24, 48 and 72 h,
respectively (Figure 2 B and C). Furthermore, exposure
of cells to 0.17 μM MTA led to a transient arrest at the S
phase, increasing cell population at this stage after 24 h
and 48 h of treatment, respectively.
Caspases participated in MTA-mediated apoptosis
As caspases are the major mediators of apoptosis, we
assessed the activity of caspases-2, -3, -8, -9, and −10 in
human MTA-treated and untreated cells using a caspase
colorimetric assay. MTA exposure for 24 h induced acti-
vation of initiator caspases −2 and −10, together with
executioner caspases −3 and −9, with maximal activation
being reached after 72 h of treatment (Figure 3A).
To clarify the role of the individual caspases in
MTA-induced apoptosis in melanoma cells, we per-
formed caspase-blocking experiments. Pre-treatment
of Hs294T cells with a pan-caspase inhibitor, or with
inhibitors to caspase-2, -3, -9 or −10, significantly
inhibited MTA-induced apoptosis (Figure 3B). (Similar
profiles were observed with the other human melan-
oma cell lines; not shown). These results indicate that
this apoptotic process in human melanoma cells is
mostly caspase-dependent, but do not rule out the
possibility that caspase-independent factors may also
participate in this process.
Involvement of p53
It is well know that p53 plays a very important role in
apoptotic cell death and development. Since we found
that MTA did not induce any cytotoxic effect on the
H1299 cell line, which lacks p53 expression, we evalu-
ated the effect of MTA on p53 gene expression by
RT-PCR in the four human melanoma cell lines and
found that it led to an increase in p53 gene and protein
expression (Figure 4A and Figure 6C). Given the strong
role of p53 in regulating cell cycle arrest and preventing
cell cycle replication during intra-S-phase checkpoint ac-
tivation, we examined the cell cycle progression in
HT144 cells after p53 activity inhibition by PFT-alpha.
We observed a reduced number of cells at s-phase after
p53 inhibition, suggesting a p53-regulated cell cycle ar-
rest. (Figure 4B).
To asses the hypothesis that MTA induces p53 expres-
sion due to DNA damage, we performed the Comet
assay on MTA-treated and untreated cells and found sig-
nificant DNA strand breaks after early MTA exposure
(Figure 4C).
Tumoral cells, after exposure to chemotherapeutic
agents typically respond by increasing intracellular ROS
levels [5] via mitochondria. This increment can lead to
DNA damage and apoptosis. We measured the intracel-
lular ROS levels after MTA exposure and found thatROS levels significantly increased after 18 h of treatment,
with maximum levels being reached after 48 h (Figure 4D:
results from the HT144 cell line are representative of all
melanoma cell lines). Next, we pretreated melanoma cells
with 10 mM NAC 1 h prior to MTA exposure to reduce
ROS accumulation and assessed viability, DNA damage and
p53 expression. We found that NAC reversed cytotoxicity
and reduced DNA damage and p53 expression (Figure 4 A,
C, E).
MTA activated a mitochondrial apoptosis pathway
The fact that MTA increased intracellular ROS levels
suggested that MTA might involve changes in mitochon-
drial function. Thus, we analysed the mitochondrial
membrane potential (ΔΨm) by flow cytometry. We
found early mitochondrial membrane hyperpolarization
in the A375 cell line, which has been interpreted by
some authors as an early sign of apoptosis [12-14], fol-
lowed by a later ΔΨm depolarization, pointing to loss of
mitochondrial membrane integrity (Figure 5A). Similar
results were obtained with HT144, Hs294T, MeWo and
Calu-3 cells (data not shown).
To further corroborate the role of mitochondria in
MTA-induced apoptosis, we analysed the release of the
mitochondrial proteins cyt-c and AIF, to the cytosol.
Confocal microscopic analysis of untreated cells showed
that cyt c and AIF displayed a peripheral punctuate
immunolabeling pattern consistent with mitochondrial
staining. Addition of MTA caused redistribution of cyt c
and AIF to the cytosol, as shown by a more diffuse, faint
staining (Figure 5B). Western blot analysis further con-
firmed that upon treatment with MTA, the levels of cyt
c and AIF in the mitochondrial fraction were reduced, in
contrast to their levels in the cytosol which increased
significantly (Figure 5C).
Apoptosis-effectors genes
In order to analyze changes in expression of other pos-
sible apoptosis-effector genes, we analysed the behaviour
of three p53-related genes which have been linked with
the malignant transformation of melanocytes and with
resistance to chemotherapy: BBC3 (PUMA), LRDD
(PIDD) and Mcl-1 (Figure 6A). Expression of target
genes was performed by real-time RT-PCR and raw data
processed by the ΔΔCt method using human RPLPO
gene as internal calibrator and MTA-unexposed cells as
reference. We found that PUMA, PIDD and Mcl-1 genes
were upregulated upon MTA treatment. Taken into ac-
count that these genes are highly regulated by p53 and
in order to confirm the involvement of p53 in this
MTA-related death, we performed a transient silencing
of p53 by siRNA. Real-time RT-PCR assays resulted in a
significant reduction of PIDD and Mcl-1 mRNA levels
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Figure 3 MTA induced caspase-dependent apoptosis. (A) Kinetics of caspase cascade activation. Induction of apoptosis in melanoma cells by
MTA was accompanied by activation of caspases-2, -3, -8, -9 and −10. Hs294T cells were treated with 0.84 μM MTA for the indicated time points.
Total cell lysates were obtained according to the manufacturer’s instructions. Assays were performed in triplicate in 96-well plates. Caspase activity
results are represented as a fold change of the control, comparing obtained results (ORmta) with the activity obtained for MTA-untreated cells
(ORcontrol) by computing ORmta/ORcontrol. Caspase-2 and −10 activities were enhanced after only 24 h, pointing to their role as inititor
caspases. The activity of caspase-3 and −9 also increased significantly after 24 h MTA exposure, confirming their executioner role in this process.
After 48 h MTA treatment, caspase-8 activity had also significantly increased, in addition to further increases in caspase-2 and −3 activities. Data
represent mean ± SD of three determinations from three separate experiments. (B) Hs294T cells were pretreated with or without caspase
inhibitors for 1 h and then challenged with 0.84 μM MTA for 72 h. Cell viability was assessed using the XTT assay. Blockade with the pancaspase
inhibitor (z-VAD-FMK) inhibited significantly but not totally the MTA effect. The most effective caspase inhibitors were those which inhibited
caspase-2 (z-VDVAD-FMK), caspase-3 (z-DEVD-FMK), caspase-9 (z-LEHD-FMK) and caspase-10 (z-AEVD-FMK) which confirmed the role of these
caspases in mediating the effects due to MTA. The caspase-8 inhibitor (z-IETD-FMK) did not significantly reverse the MTA effect. These results are
representative of three independent experiments. Similar results were obtained for all melanoma cell lines.
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expression of PUMA appeared to be p53-independent
given that p53 silencing did not cause any significant
change, suggesting an alternative regulation (Figure 6A).
Despite the increased mRNA levels obtained by real-
time RT-PCR, analysis of PUMA protein by western blot
showed invariable levels after MTA treatment (Figure 6B).
In the same way, Mcl-1 protein analysis by western blotshowed a decrease of Mcl-1 upon MTA treatment, con-
trary to the increment observed at mRNA level. This
decrement on Mcl-1 protein, as well as the gene expres-
sion, seemed to be p53-dependent (Figure 6C).
Discussion
The results of the present study indicate that MTA is an ac-

















































Figure 4 MTA upregulated p53 expression, via DNA damage and intracellular ROS accumulation (A) p53 expression was assessed by RT-PCR
after 24 h treatment with 0.84 μM MTA. Raw data was extracted by the ΔΔCt method and expression results are represented as fold change relative to the
expression of not exposed cells (control). MTA induced an increment of p53 expression comparing with controls. This increment was reduced when
intracellular ROS levels were blocked with 10 mM NAC. These results are the mean of three independent experiments. (B) The role of p53 in cell cycle
progression was verified by HT144 cell cycle distribution analysis by flow cytometry after inhibition of p53 transcriptional activity by PFT. Results are
represented as the percentage of cells in S-phase. MTA-untreated cells (control) are represented in black, PFT-only treated cells in green, 0.17 μM MTA-only
treated cells in blue and cells treated with both PFT and 0.17 μM MTA in red. MTA-induced cell cycle arrest at S-phase was avoided when inhibiting p53
activity. (C) DNA damage was analysed by Comet assay. Cells were exposed to 0.84 μM MTA for 24 or 48 h, after which double/single strand breaks were
apparent. Less damage was observed when intracellular ROS levels were inhibited with 10 mM NAC. Illustrated fields are representative; magnification, 40 x.
(D) MTA increased the level of ROS production. Intracellular ROS levels were measured by flow cytometry. Cells were exposed to 0.84 μM MTA for the
indicated times before incubation with DCFH-DA for 60 min at 37°C. A significant increase in ROS production was apparent after 18 h in all melanoma cell
lines. The graph illustrates the behaviour of the A375 cell line. (E) Cells were pretreated with 10 mM NAC before 0.84 μM MTA exposure. MTA-induced
cytotoxicity was found to be inhibited in all employed melanoma cell lines when ROS was blocked. Results are expressed as the mean of three
independent experiments, each one performed in triplicate.
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Figure 5 Apoptosis effectors genes. (A) p53 siRNA transfected and non- transfected cells were treated with MTA (0.84 μM) for 48 h before RNA
extraction. Later, the expression of p53, and of the p53-related genes PUMA (BBC3), PIDD (LRDD) and Mcl-1 were analysed by RT-PCR. Results are
represented in a heatmap showing the fold change of expression in three human melanoma cell lines, where upregulation is shown in red and
downregulation in blue as shown on the rule on the right. We found that MTA induced the upregulation of PUMA, PIDD and Mcl-1 mRNA in all
cell lines. However, when silencing p53 by siRNA, p53 was downregulated and there was a decreased upregulation of PIDD and Mcl-1 expression
comparing with non-p53 silenced cells, pointing to a role of p53 in their regulation. PUMA expression did not change when p53 was silenced
comparing with its expression in non-silenced cells, pointing to a p53-independent regulation. (B) Immunoblotting of cell lysates from cells
treated with 0.84 μM MTA for the indicated time periods using antibodies specific for the indicated proteins. No changes in PUMA protein levels
were observed and Mcl-1 protein appeared to fall after MTA treatment, suggesting that MTA may also exert its effect via postranscriptional
modifications. (C) Immunoblotting of cell lysates from A375 cells with or without transiently silenced p53 by siRNA treated with 0.84 μM MTA for
48 h. On top, MTA induced the increment of p53 protein and around a 60% p53 reduction was silenced by siRNA assay. Middle, MTA induced a
p53-dependent downregulation of Mcl-1 protein. Under each immunoblot ratios are shown, which the result of the normalisation of the raw
volume of each sample with the corresponding actin’s value and the subsequent relativisation to the control. The blots were stripped and
reprobed with actin which served as loading control.
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Figure 6 MTA-induced apoptosis involved mitochondria (A) MTA induced mitochondrial membrane damage in human melanoma cells as
indicated by ΔΨm collapse. Cells were incubated with 0.84 μM MTA for the indicated times. Subsequently, the mitochondrial membrane potential was
measured by staining the cellls with 40 nM DiOC6. In the histogram, the curve shifted to the right, which indicates retention of the dye in the
mitochondria (an early feature of apoptosis), followed by shifting of the curve to the left after 48 h due to collapse of the mitochondrial membrane
potential. This figure is representative of 3 independent experiments. Similar values were obtained for the 4 melanoma cell lines and Calu-3 (data not
shown). (B) MTA induced the release of cyt c and AIF from mitochondria. Cells were treated with 0.84 μM MTA for 48 h before immunocytochemistry. In
untreated cells, cyt-c and AIF (green) exhibited a punctuate pattern which corresponds to the mitochondrial localization of these proteins. After 48 h of
MTA exposure cyt-c and AIF immunoreactivity consisted of a diffuse pattern, indicative of their localization in the cytosol after the released from the
mitochondria. This diffuse pattern of immunoreactivity was seen in cells which presented a fragmented nucleus (blue), indicative of apoptosis. (C)
Immunoblotting of cell lysates from cytosolic and mitochondrial extracts of cells treated with 0.84 μM MTA for the indicated time periods using antibodies
specific for the indicated proteins. The blots were stripped and reprobed with actin which served as loading control. Cyt c and AIF levels can be seen to
decrease in the mitochondrial fraction while concomitantly increasing in the cytosolic fractions of MTA-treated cells.
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arrest and caspase- and mitochondrial-mediated apoptosis.
Induction of apoptosis is currently employed as an end
point by which the efficacy of new therapeutic agents can
be assessed in preclinical studies. Our results suggest that
the efficacy of MTA in the treatment of human melanoma
should be assessed by clinical trials, particularly because
MTA is already in use for the treatment of other malignant
diseases. Moreover, MTA is a well tolerated agent with ac-
ceptable toxicity if folic acid and vitamin B12 are prescribed
with it [15,16].
Various in vitro and in vivo studies have examined the
effects of MTA on various human tumour cells. Most of
these studies have revealed that MTA, either alone or in
combination with other drugs, can inhibit cell growth or
induce a cytotoxic effect on tumour cells, such as breast,
pancreas, lung and colon cancer cells [17]. In vivo, MTA
has been administered in combination with other drugs
such as platinum, gemcitabine and other antimetabolites
and antitubulin agents, using EMT-mammary carcinoma,
HCT116 colon cancer and H460 NSCLC xenografts in
nude mice [18]. Importantly, MTA is currently used for
the treatment of mesothelioma and non-small cell lung
cancer, and has demonstrated clinical activity, either
alone or in combination with the platinum compounds
vinoralbine and gemcitabine, in a broad array of other
solid tumors [15]. However, to our knowledge, no studies
have been conducted on the effect of MTA on human
melanoma, either in vitro or in vivo.
The current treatment options for patients with meta-
static melanoma are limited and noncurative in the majority
of cases. According to the American Joint Committee on
Cancer, the usual outcome for patients with advanced meta-
static melanoma (stage IV) remains bleak, with a median
survival of six to ten months and less than 5% of patients
surviving for more than five years [19-21]. Therefore, the
identification of novel compounds and new strategies for
more efficient treatment of this fatal disease is warranted.
The testing of available compounds with known effects in
other cancer therapies is a good starting point. Most of the
therapeutic strategies used against cancer, such as immuno-
therapy, chemotherapy and irradiation, involve the induc-
tion of apoptosis in cancer cells [22]. Thus, one of the most
important approaches for developing future cancer
therapies is to understand the mechanisms by which suc-
cessful therapies induce apoptosis.
Previous studies on the mechanism of action of MTA
have shown that it inhibits cell proliferation and induces
apoptosis in the cells of solid tumors [17,23] . In the current
work, we studied the effect of MTA on four human melan-
oma cell lines. In addition, we examined MTA effects on
two NSCLC cell lines (H1299 and Calu-3), which can be
considered to be positive controls, since MTA is already
used to treat this type of tumour. Our results revealed thatMTA activates caspase cascades, and treatment with pan-
caspase inhibitors significantly prevented MTA-induced
apoptosis in human melanoma cells. This inhibition was
not complete, indicating that other caspase-independent
pathways may also participate in this cell death process.
Two pieces of evidence support the role of caspase-2
and −10 as key factors in initiating the MTA-mediated
apoptotic process: first, these are the first caspases to be
activated upstream of caspase-3 and −9 activation, and
second, specific caspase-2 and −10 inhibitors effectively
prevented MTA-induced apoptosis. The exact mechanism
of caspase-2 and −10 activation is still unclear. Some
reports have shown that caspase-2 and caspase-10 are ini-
tiator caspases related to the death receptor pathway
[24,25]. In contrast, our results suggest that caspase-2 and
−10 activation occurs upstream of caspase-8 activation and
independent of the cell death receptors, since caspase-8 ac-
tivation followed activation of caspase-2 and caspase-10,
and the caspase-8 inhibitor was unable to significantly pre-
vent cell death induced by MTA. In accordance with our
results, other groups have reported that caspase-8 can be
activated downstream of caspase-3 activation and independ-
ent of the death receptor pathway [26]. Recently, it was
reported that caspase-2 and −10 can be recruited and acti-
vated by DNA damage [8,27]. To address this, we examined
the genotoxic effect of MTA in human melanoma cells
through single cell gel electrophoresis (comet assay). Our
findings provide the first evidence that the earliest structural
change induced by MTA in human melanoma cells is DNA
damage after 24 h of treatment. Furthermore, this induced
DNA damage could be the basis for the arrest of cells in the
S-phase of the cell cycle detected in cells after MTA treat-
ment. In accordance with our results, previous studies have
shown that cell cycle arrest may occur as a result of DNA
damage, in order to allow DNA repair and prevent entry
into mitosis in the presence of damaged DNA [27,28].
Recent studies suggest that mitochondria could function
as the principle sensor in cells, and that the release of
mitochondrial factors, such as cyt c, AIF and other pro-
teins, is the critical event governing cell fate [29,30]. Cas-
pase-2 activation is known to be able to control the
progress of apoptosis by regulating mitochondrial mem-
brane integrity and mitochondrial potential[31]. Our study
of the effect of MTA on the mitochondrial membrane po-
tential corroborates this claim, since we found MTA
induced hyperpolarisation as an early sign of apoptosis
[5,32] followed by hypopolarization and mitochondrial
membrane collapse. To further confirm the involvement
of mitochondria in MTA-induced apoptosis, we studied
the release of cyt-c and AIF from mitochondria to the
cytosol. We found that MTA released cyt-c from the mito-
chondria to the cytosol and activates caspase-9 [33]. Fur-
thermore, the specific caspase-9 inhibitor was the most
powerful inhibitor of MTA-induced apoptosis. The release
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cytochemistry and Western blot studies. Since AIF is a fac-
tor which produces apoptosis by acting directly on the
nucleus, independent of caspase activation [34], this
finding is compatible with the idea that MTA can induce
both caspase-dependent and –independent apoptosis.
One of the most reproducible inducers of apoptosis is
mild oxidative stress. The mechanism by means of which
an oxidative stimulus can activate the caspase cascade dur-
ing apoptosis has not been fully characterized; neverthe-
less, oxygen and its compounds is known to be able to
deplete reduced glutathione or damage the cellular antioxi-
dant defence system [35]. This leads to increased intracellu-
lar levels of ROS which are responsible for inducing DNA
damage and p53 activation with subsequent apoptosis
[4,28,36]. Furthermore, some proapoptotic agents, such as
certain histone deacetylase inhibitors, induce caspase-inde-
pendent apoptosis through the generation of ROS [37].
Based on these reports and our finding that MTA induces
DNA damage, we examined the effect of MTA on the gen-
eration of ROS. MTA was found to generate a significant
increase in the levels of ROS at the early stages of apoptosis,
even before the caspase cascade activation. In addition, we
found that pretreatment of melanoma cells with NAC sig-
nificantly decreased DNA-damage, p53 expression and
apoptosis in response to MTA.
It is well known that p53 is able to arrest the cell cycle,
activate DNA repair proteins when DNA has sustained
damage, and initiate apoptosis if the damage is irreparable
[31,38]. To assess the hypothesis that MTA induces p53 ex-
pression caused by DNA damage, we studied the expression
of p53 and related genes upon MTA exposure. We found
p53 upregulation as a direct consequence of ROS accumu-
lation, since pretreatment with NAC was found to prevent
this altered expression. Also, knockdown of p53 functional
activity by PFT-alpha resulted in a significant reduction of
MTA-induced cell cycle arrest at S-phase. However, no sig-
nificant reduction of cells undergoing subG0-G1 was
detected when inhibiting p53 functional activity upon MTA
exposure.
Subsequently, we assessed the expression of three
p53-related genes which are relevant apoptosis inducers:
PUMA, PIDD and Mcl-1. MTA provoked a p53-dependent
expression of Mcl-1 and PIDD, together with a p53-
independent PUMA regulation, since it kept an equal
expression pattern next to the transient knockdown of
p53. Furthermore, western blot analysis of PUMA
protein did not show any relevant change upon MTA
treatment, suggesting a postranscriptional regulation
of PUMA and playing down the importance of PUMA
in this MTA-induced cell death.
PIDD is a protein that has been shown to be positively
regulated by p53 and to induce cell apoptosis in response
to DNA damage [8,27,38]. This up-regulation of PIDDmay result in a RAIDD and caspase 2 enhanced recruit-
ment in order to form the PIDDosome complex, which
induces the activation of caspase 2 as an initiator of the
caspase cascade, as has been reported elsewhere [31,39].
Finally, we found a possible cause-effect link between p53
and Mcl-1 regulation, because transient knockdown of p53
resulted in a lower increment of Mcl-1 gene expression fol-
lowing MTA exposure in human melanoma cell lines. Al-
though, similarly to PUMA, the elevated mRNA levels of
Mcl-1 obtained by real-time RT-PCR did not correlate with
the marked lower levels of Mcl-1 protein, despite the pro-
tein decrement appeared to be also p53-dependent. As
some authors have stated, this kind of disparities are con-
sistent with microRNA regulation of translations, where
mRNA levels remains unaltered by the microRNA activity
given that they exert their activity through the maturation
or nuclear export process. P53 has been reported as a po-
tentially regulator of microRNA, monitoring the expression
of miRNA which are able to bind with the promoter region
of Mcl-1 or miRNAs affecting the postranscriptional regula-
tion blocking the synthesis of protein [40-42].
This MTA-induced p53-dependent regulation of Mcl-1
support the proposal of this antifolate as a potential thera-
peutic agent, since it has been suggested that upregulation
of Mcl-1 represents an early event associated with melano-
cyte malignant transformation and chemotherapy resistance
[43,44]. In addition, Mcl-1 is considered to be a relevant
player in the induction of apoptosis in melanocytes through
Apaf-1, cyt-c or Bax inhibition, and is considered to be a
suitable molecular target for enhancing chemosensitivity in
human melanoma [45-47].
All together these results and given the fact that de-
generacy is a common event in biology, a single activa-
tion of p53 might not be essential for cell cycle
progression, and apoptosis might not only depend on
p53 activity but its induction seems to have a relevant
role in regulating through both direct and indirect
mechanisms the expression of decisive executioners of
MTA-induced apoptosis.
Conclusions
We found that MTA induced DNA damage and mitochon-
drial-mediated apoptosis in human melanoma cells in vitro
and that the associated apoptosis was both caspase-
dependent and –independent. These findings may have
therapeutic relevance for the future treatment of human
malignant melanoma. Our results do not shut the door to
additional pathways bolstering the apoptotic stimulus likely
to be important in the MTA-induced apoptosis. Future
studies will be aimed at elucidating the precise
p53-mediated regulation mechanisms and studying the syn-
ergistic effect of MTA with other standard chemotherapeu-
tic agents currently in use for melanoma. Furthermore, in
the light of favourable clinical experience with MTA for
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clinical trials on the effect of MTA on human metastatic
melanoma.
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